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Abstract.  The in vitro effect of recombinant human 
bone morphogenetic protein-2 (rhBMP-2) on osteo- 
genic and myogenic differentiation was examined in 
two clonal cell lines of rat osteoblast-like cells at 
different differentiation stages, ROB-C26 (C26) and 
ROB-C20 (C20).  The C26 is a potential osteoblast 
precursor cell line that is also capable of differentiat- 
ing into muscle ceils and adipocytes; the C20 is a 
more differentiated osteoblastic cell line. Proliferation 
was stimulated by rhBMP-2 in C26 cells, but inhibited 
in C20 cells, rhBMP-2 greatly increased alkaline phos- 
phate (ALP) activity in C26 cells, but not in C20 
cells. The steady-state level of ALP mRNA was also 
increased by rhBMP-2 in C26 cells, but not in C20 
cells. Production of 3',5'-cAMP in response to 
parathyroid hormone (PTH) was dose-dependently en- 
hanced by adding rhBMP-2 in both C26 and C20 
cells, though the stimulatory effect was much greater 
in the former. There was neither basal expression of 
osteocalcin mRNA nor its protein synthesis in C26 
cells, but they were strikingly induced by rhBMP-2 in 
the presence of lot,25-dihydroxyvitamin D3.  rhBMP-2 
induced no appreciable changes in procollagen mRNA 
levels of type I and type UI in the two cell lines. Dif- 
ferentiation of C26 cells into myotubes was greatly in- 
hibited by adding rhBMP-2. The inhibitory effect of 
rhBMP-2 on myogenic differentiation was also ob- 
served in clonal rat skeletal myoblasts (L6). Like 
BMP-2, TGF-fll inhibited myogenic differentiation. 
However, unlike BMP-2, TGF-fll decreased ALP ac- 
tivity in both C26 and C20 cells. TGF-/$1 induced nei- 
ther PTH responsiveness nor osteocalcin production in 
C26 cells, but it increased PTH responsiveness in C20 
cells. These results clearly indicate that rhBMP-2 is 
involved, at least in vitro, not only in inducing dif- 
ferentiation of osteoblast precursor cells into more ma- 
ture osteoblast-like cells, but also in inhibiting myo- 
genic differentiation. 
CTOPIC bone formation is  elicited at intramuscular 
sites by implantation  of bone inducing factors con- 
tained in demineralized bone matrix (28, 35,  36). 
This indicates that cells of the osteoblast lineage have a close 
relationship with those of the muscular lineage in their on- 
togeny, and the development of the two cell lineages may be 
mutually regulated by some factor(s) stored in bone matrix. 
The components and the action mechanism of these bone in- 
ducing factors had long remained obscure.  This is mainly 
due to the difficulties of purification of these factors and the 
lack of suitable in vitro bioassay systems. 
Recently, a number of laboratories have isolated bioactive 
proteins which induce cartilage and/or bone formation at the 
sites implanted (1, 13, 30, 39, 40). Human cDNAs for seven 
different  bone  morphogenetic proteins  (BMPs), t  BMP-1, 
1. Abbreviations used in this paper: ALP, alkaline phosphatase; BMP, bone 
morphogenetic protein; PTH, parathyroid hormone; rh, recombinant hu- 
man; TGF-15, transforming growth factor-~. 
BMP-2  (BMP-2A[41]), BMP-3  (osteogenin  [13]), BMP-4 
(BMP-2B[41]), BMP-5, BMP-6  (Vgr-1 [141), and  BMP-7 
(OP-1125, 30]) have been cloned (41, 42).  The sequences 
deduced from these cDNAs  have  indicated that  BMP-2 
through BMP-7 are members of transforming growth factor- 
fl (TGF-fl) superfamily (14, 25, 41, 42). Furthermore, active 
recombinant human bone morphogenetic  protein-2 (rhBMP- 
2) has been produced, which formed bone tissue  in vivo 
when it was implanted (40). Although several bone-inducing 
factors were purified from bone matrix, the direct action of 
the isolated proteins on the osteoblastic cell lineage has not 
been fully investigated, except for osteogenln (37, 38). Fur- 
thermore, the biological action of the factors on nonskeletal 
tissues has not been extensively explored; since their biolog- 
ical activity has been evaluated only by their in vivo implan- 
tation at ectopic sites (1,  13, 30, 39, 40, 41). 
To understand more precisely the mechanism of actions of 
these bone-inducing factors, a suitable in vitro experimental 
model is required. We recently established  and character- 
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calvariae (44). These cell lines express various osteoblastic 
properties, reflecting different maturation  stages.  Of these, 
two cell lines, ROB-C20 (C20) and ROB-C26 (C26), exhibit 
the extremes in maturation  stages of osteoblasts.  The C20 
expresses a wide spectrum of ostcoblastic properties, indi- 
cating that it is a mature osteoblastic cell line (44). In con- 
trast, the C26 has characteristics of an osteoblast progenitor 
cell  line,  retaining  the potential  to  differentiate  into both 
myotubes and adipocytes (44). But neither of these cells pro- 
duced osteocalcin (bone Gla protein, BGP), a bone matrix 
protein specifically produced by osteoblasts  (11). C20 and 
C26 cells thus may be useful tools for determining the role 
of BMPs in osteogenic and myogenic differentiation. 
Here we show that the two cell lines, C20 and C26,  are 
responsive to rhBMP-2:  this recombinant cytokine not only 
stimulated proliferation and differentiation  of C26 cells, but 
inhibited myogenic differentiation  of C26 cells in vitro.  We 
also demonstrate that rhBMP-2  strikingly induces the syn- 
thesis of osteocalcin in the presence of 1  or, 25-dihydroxyvita- 
rain D3 in C26 cells. 
Materials and Methods 
Recombinant Human Bone Morphogenetic Protein-2 
and Transforming Growth Factor-~  l 
Recombinant human bone morphogenetic protein-2 (rhBMP-2)  was pro- 
duced by CHO (Chinese hamster ovary) cells and purified  as described 
previously  (40).  The recombinant protein used in the present study was 
80-90%  pure as judged by silver-stained bands on SDS gels and also by 
NH2-terminal  sequencing.  The in vivo ectopic bone formation assay  re- 
vealed that this material was active at 1 #g, the lowest dose level tested 7 d 
after implantation. 
TGF-B1 purified  from human platelets was purchased from R & D Sys- 
tems, Inc.  (Minneapolis,  MN). 
Cell Culture 
Two clonai rat osteoblastic cell lines, ROB-C20 (C20) and ROB-C26 (C26), 
were isolated from newborn rat calvatia (44). The two cell lines were plated 
into 24-multiwell  plates (Falcon Labware,  Lincoln Park, NJ) at a seeding 
density of 7  x  103  cells per  well  and cultured  with a-MEM  (Gibco 
Laboratories, Grand Island, NY) containing i0% FBS (HyClone Laborato- 
ties, Logan, UT) and antibiotics (100 U/rnl penicillin and 100 #g/ml strep- 
tomycin). To determine the role of rhBMP-2 in the myogenic differentiation, 
we also used a clonal rat cell line of skeletal muscle myoblasts (L6 cells) 
(43) obtained from the Japanese Cancer Research Resources Bank (Tsukuba 
Science City, Japan). L6 cells were maintained in DMEM (Gibco Laborato- 
ties) supplemented with 10% FBS and antibiotics. L6 cells were plated in 
4g-well tissue culture plates (Costar Corp., Cambridge, MA) at a cell den- 
sity of 1  x  lif  t cells per well.  In some experiments,  L6 cells were cul- 
tured with DMEM containing 2 % FBS to induce differentiation  of myo- 
blasts (33). 
Growth Experiments 
After C26 and C20 cells were cultured for 3 d with various concentrations 
of rhBMP-2, the cells were detached from the culture dishes by incubating 
with a trypsin/EDTA  solution (0.05% trypsin; 0.02% EDTA), and the cell 
number was counted using a hemocytometer. 
Alkaline Phosphatase Activity 
Alkaline phosphatase (ALP) activity  was  determined by an established 
technique using p-nltrophenyl-phosphate as a substrate (26).  Protein con- 
centration was determined using a BCA protein assay reagent (Pierce Chem- 
ical Co., Rockford,  IL). 
YY-cAMP  Production in Response to 
Parathyroid Hormone 
To determine 3',5'-cAMP production in response to parathyroid hormone 
(PTH), cells were preincubated for 20 rain with c~-MEM containing 0.5% 
BSA and  1 mM 3-isobutyl-l-methylxanthine.  After preincubation media 
wore removed,  cells were incubated for 8 rain with 200 ng/ml of human 
PTH (hPTH(1-34)) (provided by Dr. Hori, Toyo Jozo Co., Shizuoka, Japan) 
dissolved  in the same culture media.  The cAMP concentration in the cell 
layers was determined by RIA using a cAMP assay kit (Yamasa Co., Chiba, 
Japan). 
Myogenic Differentiation 
Myotubes appearing in the C26 cells were detected by immunoreactivity  to 
desmin, a muscle-specific  intermediate filament.  To detect desmin, cells 
were  fixed for 10 min with a cold acetone/ethanol mixture (50:50),  and 
stained for desmin by an indirect immunoperoxidase  technique using a 
mouse  anti-cow  desmin  mAb  (Labsystvms,  Helsinki,  Finland).  The 
desmin-positive cells were visualized using a biotinylated  anti-mouse IgG 
antibody (Vector Laboratories, Burlingame,  CA).  Myotubes appearing  in 
the L6 cells were identified  by morphology  according to the method de- 
scribed previously  (43). 
Northern Blot Hybridization of  ALP and Collagens 
Total  RNA  was  isolated  by the guanidine thiocyanate-cesium  chloride 
method (16). 20 #g of the isolated RNA were electrophoresed  in a  1.2% 
agarose-formaldehyde  gel, and blotted onto Hybond-N membranes (Amer- 
sham International, Amersham,  UK).  The membranes were  hybridized 
with riP-labeled eDNA probes at 65°C  in a  rapid hybridization buffer 
(Amersham International) and washed in 0.1x SSC buffer containing 0.1% 
SDS at the same temperature,  eDNA probes used were those for rat ALP 
(23),  rat procollagen cd(I) (6),  and cd(m) (12), and human ~-tubulin. 
Measurement of Osteocalcin Synthesis 
The C26 cells were treated for 3, 6, or 9 d with or without 1 #g/mi of 
rhBMP-2. The culture was incubated for the last 24 h of each culture period 
with or without 2  x  10  -s M  lc~,25(OH)2D3. Northern blot analysis of os- 
teocalcin was performed as described above using a rat osteocalcin  eDNA 
probe (3). The amount of osteocalcin secreted into the culture media was 
determined by RIA using a rat osteocalcin assay kit (Biomedical Technolo- 
gies Inc., Stoughton, MA). 
Results 
Cell Proliferation 
Fig. 1 shows the effect of rhBMP-2  on the growth of C26 and 
C20 cells. The cells were cultured  with graded concentra- 
tions of rhBMP-2, then counted on day 3. At dose levels >10 
ng/ml, rhBMP-2  increased the growth of the C26 cells, but 
it inhibited the proliferation of the C20  cells dose depen- 
dently (Fig.  1). 
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**  fects of  rhBMP-2 on the growth 
y/  of C26 (o) and C20 (e) cells. 
Cells  were  plated  in 24-well 
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Figure 2.  Dose-response  effects of rhBMP-2 on ALP activity in 
C26 (o) and C20 (e) cells. Cells were cultured with graded con- 
centrations of rhBMP-2 for 3 (A) and 6 d (B). ALP activity was 
determined by the method described in Materials and Methods. 
Data  are  means  +  SD  of three  wells. Significantly different 
from the control without rhBMP-2. (*p < 0.05; **p < 0.01; ***p 
< 0.001.) 
ALP Activity 
C20 cells exhibited basal activity of ALP approximately five 
times higher than C26  cells  in  the absence of rhBMP-2. 
rhBMP-2 stimulated ALP activity in C26 ceils but not in C20 
cells. After C26 cells were treated for 3 d with 1 #g/ml of 
rhBMP-2,  ALP  activity  was  increased  to  approximately 
twice the basal level (Fig. 2 A). On day 6, rhBMP-2 increased 
ALP activity at concentrations <1/zg/ml. The enzyme activ- 
ity attained a  level 16 times higher than the control level 
when 1 #g/ml of the peptide was added (Fig. 2 B). In C20 
cells,  in  contrast,  treatment with >10  ng/ml of rhBMP-2. 
slightly decreased the ALP activity on day 3  (Fig.  2 A). 
Treatment of C20 cells with rhBMP-2 for 6 d did not induce 
any significant changes in the enzyme activity at any concen- 
trations tested (Fig. 2 B). 
L6 cells showed a low but detectable ALP activity after 
they were cultured for 7 d (24.0 +  1.8 nmol/min per mg pro- 
tein). Treatment of L6 cells with rhBMP-2 for 6 d increased 
the enzyme activity to 29.3  +  0.4 at 10 ng/ml and 32.2  + 
1.9 at 100 ng/ml, but decreased it to 12.5  +  0.7 nmol/min 
per mg protein at 1 /zg/ml. 
PTH-dependent cAMP Production  by C26 
and C20 Cells 
Both C26 and C20 cells produced cAMP in response to 200 
ng/ml of  hPTH(1-34), but in the absence of rhBMP-2 the fold 
induction was higher in C20 cells than C26 cells on both days 
3  and  6  (Table I).  Treatment with rhBMP-2  dose-depen- 
dently increased cAMP production in the two osteoblastic 
ceils, but the C26 ceils appeared more sensitive to rhBMP-2 
than the C20 ceils. On day 6, the maximal increase by 1 #g/ 
ml of rhBMP-2 was 151-fold in the C26 cells and 58-fold in 
C20 cells. In L6 cells, there was no increase in the cAMP 
production in response to PTH in the presence or absence 
of rhBMP-2. 
mRNA Expression of  ALP and Collagens 
Northern blot analysis showed that rhBMP-2 increased the 
steady state level of the expression of ALP mRNA approxi- 
mately twofold in C26 cells, but did not increase it in C20 
cells (Fig.  3).  There was no appreciable change in the ex- 
pression of type I  and type III procollagens and/3-tubulin 
mRNAs  in the C20 and C26 cells treated with rhBMP-2 
(Fig. 3). 
Osteocalcin Synthesis 
Control  C26  cells  that  were  cultured  for  3-9  d  without 
rhBMP-2 synthesized neither detectable levels of osteocalcin 
mRNA nor protein even in the presence of 10  -s M  lot,25- 
(OH)2D3 (Fig. 4, A and B).  Treatment of C26 cells with 
1/~g/ml of rhBMP-2 for 3-9 d greatly increased the expres- 
Table L Effects of rhBMP-2 on the cAMP Production Stimulated by PTH in C20 and C26 Cells 
Amounts of cAMP produced 
Day 3  Day 6 
PTH(+)/PTH(-)  PTH(+)/PTH(-) 
Cell line  rhBMP-2  PTH(-)  PTH(+)  ratio  PTH(-)  PTH(+)  ratio 
C26 
C20 
ng/ml  pmol/well 
0  1.3  5:0.0  2.5  +  0.0  1.9  0.8  +  0.0  12.2  +  0.1  15.0 
1  1.6  +  0.1  3.1  +  0.2  2.0  0.8  +  0.0  10.1  +  0.1  13.0 
10  1.5  +  0.0  4.2  5:0.4  2.8  0.8  +  0.0  14.3  +  0.1  17.9 
100  1.7  +  0.0  20.0  +  1.5  11.5  1.0  +  0.0  60.4  +  2.4  62.5 
1,000  2.5  +  0.1  110.0  +  7.6  48.2  2.5  +  0.1  375.0  +  9.8  151.4 
0  1.4  +  0.2  4.2  +  0.5  3.0  2.4  +  0.1  62.4  +  0.8  27.9 
1  1.1  +  0.1  4.8  +  0.4  4.1  2.0  +  0.1  48.0  +  2.0  24.7 
10  1.5  +  0.1  6.3  +  0.2  4.2  2.5  +  0.2  66.9  +  1.3  26.7 
100  1.4  Jr 0.1  14.7  +  1.7  10.7  2.1  5:0.1  72.7  5:1.6  35.3 
1,000  1.8  +  0.3  22.0  +  1.2  12.5  1.6  +  0.1  92.5  +  4.1  58.3 
Cells were cultured for 3 or 6 d with graded concentrations of rhBMP-2.  On days 3 and 6, cells were treated for 8 min with 200 ng/ml of hPTH(I-34)  and the 
amount of cAMP  produced was determined.  Data are means  +  SEM of three wells. 
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ysis of the mRNA expression 
of ALP and procollagens of 
cd(I) and ~1(III). Total RNAs 
were  isolated from C26  and 
C20 cells after treatment for 
3 d with 1 #g/ml of rhBMP-2. 
20 #g of  total RNA were elec- 
trophoresed in agarose gel and 
hybridized with the respective 
32p-labeled eDNA  probes  as 
described  in  Materials  and 
Methods. ~tub, B-tubulin. 
sion of osteocalcin mRNA (Fig. 4 B). On day 3, a low level 
of osteocalcin  mRNA  was  expressed  only in  the  lo~,25- 
(OH)2D3-treated cells. On days 6-9, the levels of mRNA in- 
creased even in the absence of lot,25(OH)2D3,  and its ex- 
pression was strikingly increased by the treatment with 1,, 
25(OH)2D3 for 24 h (Fig. 4 B). The amounts of osteocalcin 
secreted into the culture media were closely related to the 
mRNA levels of osteocalcin (Fig. 4, A and B). 
Myogenic Differentiation 
When C26 cells became confluent, some of them spontane- 
Figure 4. Induction of osteoealcin synthesis by rhBMP-2 in C26 
cells. C26 cells (7.9 x  104 cells) were inoculated in 60-mm  2 cul- 
ture  dishes.  After preculturing  the  cells  for 24  h,  rhBMP-2 (1 
#g/ml) was added and the cells were further cultured for 3, 6, or 
9 d. The dish was treated for the last 24 h of each culture period 
with or without 2  x  10  -8 M lc~,25(OH)2D3. (A) The amount of 
osteocalcin secreted into culture media as determined by RIA using 
the method described in Materials and Methods. (B) mRNA ex- 
pression for osteocalcin. 20 t~g of total RNA isolated from each 
sample were electrophoresed in agarose gel and hybridized with a 
32p-labeled eDNA probe for osteocalcin as described in Materials 
and Methods. OC, osteocalcin, B-tub, B-tubulin. 
ously differentiated into desmin-positive myotubes (Fig.  5 
A). Adding rhBMP-2 dose-dependently decreased the num- 
ber of desmin-positive myotubes at dose levels >1 ng/ml of 
the peptide (Figs. 5 B and 6 A). Numerous myotubes also ap- 
peared when L6 cells were cultured with the inducing culture 
media (Fig. 5  C).  Treatment of L6 cells with rhBMP-2 at 
higher concentrations than  1 ng/ml  similarly reduced the 
number of myotubes dose dependently (Figs. 5 D and 6 B). 
Effects of TGF-B1 on Osteoblastic and 
Myogenic Differentiation 
BMP-2 is a member of the TGF-/~ superfamily (41).  We ex- 
amined the effect of TGF-B1 on osteoblastic and myogenic 
differentiation to determine whether the effects shown in this 
study are specific to BMP-2.  Like BMP-2,  TGF-B1 dose- 
dependently decreased the number of myotubes appearing in 
C26 cells (Fig. 7 C). However, unlike BMP-2, treatment of 
C20 cells with 0.1-10 ng/ml of  TGF-BI for 6 d decreased ALP 
activity dose dependently (Fig. 7 A). TGF-BI also suppressed 
ALP activity in C26 cells, though the inhibitory effect was 
smaller than in  C20 cells (Fig.  7 A).  TGF-BI  showed no 
significant effect  on the PTH-dependent cAMP production in 
C26 cells at any concentrations tested (Fig. 7 B), but it in- 
creased PTH responsiveness in C20 cells (Fig. 7 B). Treat- 
ment of C26 cells for 6 d with 0.1-10 ng/ml of TGF-BI in- 
duced no osteocalcin production even in the presence of lo~, 
25(OH)2D3. 
Discussion 
The present study clearly demonstrates that the recombinant 
BMP-2  poly-peptide  affects  proliferation  and  differentia- 
tion of certain osteoblastic cells in vitro.  To determine if 
rhBMP-2 had differential effects on osteoblasts at varying 
stages of differentiation, we used two clonal osteoblast-like 
cell lines at different stages of differentiation: C26 cells are 
osteoprogenitor cells, also retaining potentials to differenti- 
ate into muscle ceils and adipocytes; C20 cells are more 
differentiated osteoblast-like cells (44). rhBMP-2 stimulated 
the growth of C26 cells but slightly inhibited the prolifera- 
tion of C20 cells. The stimulatory effect of rhBMP-2 on the 
osteoblastic phenotype was much greater in C26 cells than 
in  C20  cells.  This  indicates  that  rhBMP-2  preferentially 
stimulates proliferation and differentiation of osteoprogeni- 
tor ceils. 
At present,  osteocalcin is the only known bone-specific 
protein produced by osteoblasts (11). This protein is reported 
to appear in a later stage of osteoblast differentiation (2, 34, 
45), presumably in mature osteoblasts, whereas ALP (2, 34, 
45), PTH receptors (29), and type I collagen (31, 34, 45) ap- 
pear even in less differentiated osteoblasts.  Although C26 
cells have already acquired a low level of the latter character- 
istics, but they lack osteocalcin synthesis in an unstimulated 
state.  It  is  significant  that  rhBMP-2  induced  osteocalcin 
mRNA expression and its protein synthesis in C26 cells. Ap- 
parently rhBMP-2 induced differentiation of immature os- 
teoblastic cells into mature osteoblasts not only by increas- 
ing the expression of the constitutive phenotype present in 
progenitor cells, but also by inducing the expression of novel 
genes present only in mature osteoblasts, rhBMP-2 is the 
first cytokine that is capable of inducing osteocalcin mRNA 
expression and  its protein synthesis.  Whether other bone 
The Journal of Cell Biology.  Volume 113, 1991  684 Figure 5.  Effects of rhBMP-2 on the development of myotubes in C26 and L6 cells. (,4 and B) C26 cells were immunostained with an 
anti-desmin antibody as described in Materials and Methods. Numerous desmin-positive elongated myotubes are seen in the C26 ceils 
cultured for 7 d in the absence of rhBMP-2 (A). Note that there is a marked decrease in the number of desmin-positive myotubes in the 
C26 cells cultured with rhBMP-2 (100 ng/ml) for 6 d (B).  (C and D) Phase-contrast features of L6 cells. The cells were cultured with 
the media containing 10% FBS for the first 3 d then with the media containing 2 % FBS for the last 3 d. Numerous multinucleated myotubes 
are seen in the L6 cells cultured in the absence of rhBMP-2 (C). Treatment with rhBMP-2 (100 ng/ml) for the last 3 d greatly inhibited 
the appearance of myotubes (D).  Bars, 200/~m. 
Figure 6. Dose-response effects of rhBMP-2 on the development of 
myotubes in C26 cells (A) and L6 cells (B). Myotubes appearing 
in each cell line were identified as  described in Materials and 
Methods. The number of myotubes was counted in 6.25-mm  2 at 
the central region of each well. Data are means +  SD of three 
wells. Significantly different from the control without rhBMP-2. 
(*p < 0.05; ***p < 0.001.) 
growth factors have similar effects  in inducing osteocalcin 
synthesis remains to be elucidated in the future. 
Cells  of the  osteoblastic  phenotype make  a  significant 
quality of type I  collagen.  In the present  study,  treatment 
with rhBMP-2 induced no appreciable change of expression 
of type I and type III procollagen mRNAs in C26 and C20 
cells. Collagen synthesis measured by [3H]proline  incorpo- 
ration  was  not  significantly  stimulated  by rhBMP-2  (100 
ng/ml) in C26 ceils and in calvafial cultures (unpublished 
data). No stimulation occurred in the mRNA expression for 
type I procollagen in the mouse clonal embryonic fibroblas- 
tic cells (C3H10T1/2)  (unpublished data), which responded 
to rhBMP-2 in increasing their ALP activity and PTH re- 
sponsiveness  (9).  It thus  appears  that  BMP-2 has  no ap- 
preciable effect on collagen synthesis, at least in the cell lines 
we used. 
The minimal doses of rhBMP-2 that affected proliferation 
and differentiation of C26 cells were much higher than those 
of other cytokines and growth factors.  Also, the  effective 
doses of rhBMP-2 necessary to induce ALP activity were 
>10 ng/ml in C3H10T1/2 cells (9) and mouse osteoblast-like 
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ation. (,4) Dose-response effects  of  TGF-/31 on ALP activity in C26 
(o) and C20 (o) cells. After the cells were cultured with graded 
concentrations of  TGF-/31 for 6 d, the ALP activity was determined 
by the method described in Materials and Methods. Data are means 
+  SD of three wells. (B) Dose-response effects of TGF-/31 on the 
cAMP production stimulated by PTH in C26  (o) and C20 (e) 
cells. The cells were cultured for 6 d with graded concentrations 
of TGF-/~I. Then the amount of cAMP produced was determined 
as described in Materials and Methods, after the cells were treated 
for 8 min with or without 200 ng/ml of hFrH0-34). The PTH re- 
sponse was expressed as the ratio of cAMP production by PTH- 
stimulated ceils to that by unstimulated ceils. Data are means of 
three wells in each group. (C) Dose-response effects  of TGF-/~I on 
myogenic differentiation in C26 cells. Myotubes were identified as 
described in Materials and Methods. The number of desmin-posi- 
tive cells was counted in 6.25-mm  2 at the central region of each 
well. Data are means +  SD of three wells. Significantly different 
from the control without TGF-/~I. (*p <  0.05; **p <  0.01; ***p 
< 0.001.) 
MC3T3-E1 cells (10) (unpublished data). However, this low 
responsiveness might not be due to the low specific activity 
of BMP-2. This may be explained by the difference between 
the native BMP-2 and the recombinant one, since it requires 
more rhBMP-2 than the native BMPs to induce similar ec- 
topic bone formation (40). Alternatively, it may be due to the 
sticky nature of BMP-2. Further comparative studies using 
native and  recombinant BMPs  are  needed to clarify this 
point. 
During the process of ectopic bone formation after bone- 
inducing factors are implanted into muscular tissues, these 
factors appear to alter the differentiation of muscle  cells 
around the sites applied. The present study clearly demon- 
strates  that  rhBMP-2  inhibits  myogenic differentiation in 
vitro. Apparently BMP-2 has opposite actions on osteogenic 
and myogenic differentiation in pluripotent ceils: rhBMP-2 
stimulates differentiation of mesenchymal cells into osteo- 
blastic ceils and inhibits differentiation of those cells into 
muscle cells. It is reported that cartilage formation precedes 
the osteoblast differentiation in the process of ectopic bone 
formation induced by BMP-2 (27, 28). Since myogenic cells 
are induced to differentiate into chondrogenic cells in re- 
sponse to bone matrix in vitro (18, 19, 24, 32), it will be in- 
teresting to determine whether rhBMP-2 induces differentia- 
tion of C26 cells and L6 cells into chondrogenic cells. This 
possibility is currently under investigation. 
BMP-2 is a member of the TGF-/3 superfamily (41). To de- 
termine whether the effects shown in this study are specific 
to BMPs, we compared the effects of rhBMP-2 and TGF-/31 
on osteogenic and myogenic differentiation in C26 and C20 
cells. Like BMP-2, TGF-/31 suppressed myogenic differentia- 
tion in C26 ceils. However, unlike BMP-2, TGF-/31 decreased 
ALP activity in both C26 and C20 cells. TGF-/31 stimulated 
PTH responsiveness in C20 cells, but it induced neither laTH 
responsiveness nor osteocalcin production in C26 cells. In 
vivo studies (8, 22) have indicated that TGF-/5 injected into 
periosteal regions induced new bone formaiion in rats, but 
several in vitro experiments have revealed that the effects of 
TGF-/3  on  ALP  activity  and  PTH  responsiveness  varied 
among the cells tested (4, 7, 20, 21).  The inconsistency of 
the in vitro data suggests that the action of TGF-/5 on osteo- 
blast differentiation  depends on the stage of  differentiation  of 
the ostcoblast-like cells used and the culture conditions. The 
inhibitory effects of TGF-/3 on myogenic differentiation have 
also been demonstrated in other myogenic cells (5,  17). To- 
gether, these results indicate that both BMP-2 and "I'GF-/5 
similarly inhibit myogenic differentiation, but they have dif- 
ferent actions in osteoblast differentiation. 
Although the precise role of  the respective BMPs and their 
mutual interaction in  osteoblast differentiation have to be 
elucidated in the future, it is interesting that in the recent 
finding reported by Lyons et al. (15), BMP-2, Vgr-1 (BMP- 
6), "I'GF-B1 and TGF-/~2 mRNAs are expressed in different 
populations of mesenchymal cells in the developing skeletal 
system. They also proposed the importance of the coordi- 
nated expression of several members of the "I'GF-/3 super- 
family for the control of progression of specific cell types 
through the differentiation pathways (15). It is important to 
determine the specific actin and the mutual interaction of 
various BMPs and TGF-/~s to understand the precise regula- 
tory mechanisms of osteoblast differentiation. 
In conclusion, rhBMP-2 is a bone induction factor that in- 
duces differentiation of osteoblast progenitor ceils into ma- 
ture osteoblast with  the ability to  synthesize osteocalcin. 
Also, rhBMP-2 inhibits myogenic differentiation. So it ap- 
pears that BMP-2 is involved in both in vivo osteoblastic and 
myogenic differentiation at the site of implantation. Whether 
BMP-2  affects  other  cell  diffrenfiation events  including 
chondrogenesis and adipogenesis is of considerable interest 
and is under investigation in our laboratories. 
We are grateful for providing eDNA probes to Dr. M. Noda (alkaline phos- 
phatase), Dr. B. Kream (type I procollagen) and Dr. B. de Crombrugghe 
(type m  procollagen). 
This  work  was  supported  in  part  by  grants-in-aid  (01870076  and 
01570995) from the Ministry of Science, Education and Culture of Japan. 
Received for publication 12 July 1990 and in revised form 14 January 1991. 
References 
1. Bentz, H., R. M. Nathan, D. M. Rosen, R. M. Armstrong, A. Y. Thomp- 
son, P. R. Segarini, M. C. Mathews, J. R. Dasch, K. A. Piez, and S. M. 
Seyedin. 1989. Purification  and characterization of a unique osteoinduc- 
tive factor from bovine bone. J.  Biol.  Chem. 264:20805-20810. 
2. Bronckers, A. L. J. J., S. Gay, R. D. Finkelman, andW. T. Butler. 1987. 
Developmental appearance  of Gla proteins (osteocalcin)  and alkaline 
phosphatase  in tooth germs and bones of  the rat. Bone Miner. 2:361-373. 
3. Celeste, A. J., V. Rosen, J. L. Buecker, R. Kriz, E. A. Wang, andJ. M. 
Wozney. 1986. Isolation of the human gene for bone gla protein utilizing 
mouse and  rat  eDNA  clones.  EMBO  (Fur.  Mol.  Biol.  Organ.)  J. 
5:1885-1890. 
4. Elfford,  P. R., H. L. Guenther, R. Felix, M. G. Cecchini, and H. Fleisch. 
1987. Transforming growth factur-~ reduces the phenotypic expression 
of osteoblastic  MC3T3-E1 cells in monolayer culture. Bone (Elmsford). 
8:259-262. 
5. Florini, J. R., and K. A. Magri.  1989. Effects of growth factors on myo- 
genic differentiation.  Am. J. Physiol. 256(Cell Physiol. 25):C701-C711. 
6. Genovese, C., D. Rowe, and B. Kream. 1984.  Construction of DNA se- 
quences complementary to rat cq and c~2 collagen mRNA and their use 
The Journal of Cell Biology, Volume 113,  1991  686 in  studying  the  regulation  of  type  I  collagen  synthesis by  1,25- 
dihydroxyvitamin D. Biochemistry.  23:6210-6216. 
7. Gutierrez, G. E., G. R. Mundy, D. R. Manning, E. L. Hewlett, and M. S. 
Katz.  1990.  Transforming growth factor B enhances parathyroid hor- 
mone stimulation of adenylate cyclase in clonal osteoblast-like cells. J. 
Cell PhysMl.  144:438--447. 
8. Joyce, M. E., A. B. Roberts, M. B. Sporn, and M. E. Bolander.  1990. 
Transforming growth factor-B  and the initiation of chondrogenesis and 
osteogenesis in the rat femur. J.  Cell Biol.  110:2195-2207. 
9. Katagiri, T.,  A. Yamaguchi, T.  Ikeda,  S.  Yoshild, J.  M.  Wozney, V. 
Rosen, E.  A. Wang, H. Tanaka, S. Omnra, and T.  Soda.  1990.  The 
nonosteogenic pluripotent cell line, C3H10T1/2, is induced to differenti- 
ate into osmoblastic cells by recombinant human bone morphogenetic 
protein-2. Biochem.  Biophys.  Res.  Commun.  172:295-299. 
10. Kodama, H., Y. Amagai, H. Sudo, S. Kasai, and S. Yamamoto. 1981. Es- 
tablishment  of a clonal osteogenic cell line from newborn mouse  calvaria. 
Japan J.  Oral Biol.  23:899-901. 
11. Lian, J. B., and C. M. Gundberg. 1988. Osteocalcin: biochemical consider- 
ations and clinical  applications. Clin.  Orthop.  226:267-291. 
12. Liau, G., M. Mudryj, and B. de Crombrugghe. 1985. Identification  of the 
promoter and first  exon of the mouse cd(III)  collagen gene. J.  Biol. 
Chem.  260:3773-3777. 
13. Luyten, F. P., N. S. Cunningham, S. Ma, N. Muthukumaran, R. G. Ham- 
monds, W. B. Nevins, W. I. Wood, and A. H. Reddi. 1989. Purification 
and partial  amino acid sequence of osteogenin, a protein initiating bone 
differentiation.  J. Biol.  Chem.  264:13377-13380. 
14. Lyons, K., J. L. Graycar, A. Lee, S. Hashmi, P. B. Lindquist, E. Y. Chen, 
B.  L.  M.  Hogan, and R.  Derynck.  1989.  Vgr-l, a  mammalian gene 
related  to Xenopus Vg-1, is a member of the transforming growth factor 
B gene superfamily. Proc. Natl. Acad.  Sci.  USA.  86:4554-4558. 
15. Lyons, K. M., R. W. Pelton, and B. L. M. Hogan. 1989. Patterns of ex- 
pression of murine Vgr-I and BMP-2a RNA suggest that transforming 
growth factor-B-like genes coordinately regulate aspects of embryonic de- 
velopment. Genes & Dev.  3:1657-1668. 
16. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982.  Molecular Cloning: 
A  Laboratory  Manual.  Cold  Spring  Harbor  Laboratory,  New  York. 
196 pp. 
17. Massague, J., S. Cheifetz, T. Endo, and B. Nadal-Ginard.  1986. Type B 
transforming growth factor is an inhibitor of myogenic differentiation. 
Proc. Natl. Acad.  Sci.  USA.  83:8206-8210. 
18. Nathanson, M. A., and E. D. Hay. 1980. Analysis of cartilage differentia- 
tion  from  skeletal  muscle grown  on  bone  matrix.  I.  Ultrastructural 
aspects. Dev.  Biol.  78:301-331. 
19. Nathanson, M. A., and E. D. Hay. 1980. Analysis of cartilage differentia- 
tion from skeletal muscle grown on bone matrix. II. Chondroitin sulfate 
synthesis and  reaction to  exogenous glycosaminoglycans. Dev.  Biol. 
78:332-351. 
20. Noda, M., and G. A. Rodan. 1986. Type-B transforming growth factor in- 
hibits proliferation  and expression of alkaline phosphatase in murine 
osteoblast-like cells. Biochem. Biophys. Res.  Commun.  140:55-65. 
2l. Noda, M., and G. A. Rodan.  1987.  Type ~ transforming growth factor 
(TGF~)  regulation  of  alkaline  phosphatase  expression  and  other 
phenotype-related mRNAs in osteoblastic rat osteosarcoma cells. J. Cell 
Physiol.  133:426-437. 
22. Noda, M., andJ. I. CamiUiere.  1989. In vivo stimulation of bone formation 
by transforming growth factor-B.  Endocrinology.  124:2991-2994. 
23. Noda, M., K. Yoon, M. Thiede, R. Buenage, M. Weiss, P. Henthorn, H. 
Harris, and G. A. Rodan. 1987. eDNA cloning of alkaline  phosphatase 
from  rat  osteosarcoma  (ROS  17/2.8)  cells.  J.  Bone  Miner.  Res. 
2:161-164. 
24. Nogami, H., and M.  R.  Urist.  1970.  A  substratum of bone matrix for 
differentiation  of mesenchymal cells  into  chondro-osseous tissues in 
vitro. Exp.  Cell Res.  63:404-410. 
25. (~zkaynak,  E., D. C. Rueger, E. A. Drier, C. Corbett, R. J. Ridge, T. K. 
Sampath, and H. Oppermann. 1990. OP-I eDNA encodes and osteogenic 
protein  in  the  TGF-3  family.  EMBO  (Fur.  Mol.  Biol.  O~'gan.) J. 
9:2085-2093. 
26. Partridge, N. C., D. Alcon, V. P. Michelangeli, B. E. Kemp, G. B. Ryan, 
and T. I. Martin. 1981. Functional properties of hormonally responsive 
cultured normal and  malignant rat osteoblastic cells.  Endocrinology. 
108:213-219. 
27. Reddi, A. H. 1985. Regulation of bone differentiation  by local and systemic 
factors. In Bone and Mineral Research. W. A. Peck,  editor.  Elsevier 
North Holland, Amsterdam. vol. 3.27--47 pp. 
28. ReMdi, A. H., and C. Huggins. 1972. Biochemical sequences in the trans- 
formation of normal fibroblasts in adolescent rats. Proc. Natl. Acad.  Sci. 
USA.  69:1601-1605. 
29. Rouleau, M. F., J. Mitchell, and D. Goltzman. 1988. In viva distribution 
of parathyroid hormone receptors in bone: evidence that a predominant 
osseous target cell  is not the mature osteoblast. Endocrinology.  123: 
187-191. 
30. Sampath, T. K., J...E. Coughlin, R. M. Whetstone, D. Banach, C. Corbett, 
R. J. Ridge, E. Ozkaynak, H. Oppermann, and D. C. Ruegur. 1990. Bo- 
vine osteogenic protein is composed of dimers of OP-1 and BMP-2A, two 
members of the transforming growth  factur-B  superfamily. J.  Biol. 
Chem.  265:13198-13205. 
3 I. Sandberg, M., and E. Vuorio. 1987. Localization of type I, II, and HI colla- 
gen mRNAs in developing human  skeletal tissues  by in situ hybridization. 
J.  Celt Biol.  104:1077-1084. 
32. Sato, K., and M. R. Urist. 1984. Bone morphogenetic protein-induced car- 
tilage development in tissue culture. Clin.  Orthop.  183:180-187. 
33. Spizz,  G.,  D.  Roman, A. Strauss, and E.  N.  Olson.  1986.  Serum and 
fibroblast growth factor inhibit myogenic  differentiation  through a mecha- 
nism dependent on protein synthesis  and independent of cell proliferation. 
J. Biol.  Chem.  261:9483-9488. 
34. Strauss, P. G., E. I. Closs, J. Schmidt, and V. Erfle.  1990. Gene expression 
during osteogenic differentiation  in mandibular condyles in vitro. J. Cell 
Biol.  110:1369-1378. 
35. Urist, M. R. 1965. Bone: formation by autoinduction. Science (Wash. DC). 
150:893-899. 
36. Urist, M. R., R. J. DeLange, and G. A. M. Finerman. 1983.  Bone cell 
differentiation  and growth factors. Science (Wash.  DC).  220:680-686. 
37. Vukicevic, S., F. P. Luyten, and A. H. Reddi.  1989.  Stimulation of the 
expression of osteogenic and chondrogenic phenotypes in vitro by os- 
teogenin. Proc. Naa. Acnd.  Sci.  USA.  86:8793-8797. 
38. Vukicevic, S., F. P. Luyten, and A. H. Reddi.  1990. Osteogenin inhibits 
proliferation and stimulates differentiation  in mouse osteoblast-like cells 
(MC3T3-EI). Biochem.  Biophys.  Res.  Commun.  166:750-756. 
39. Wang, E. A., V. Rosen, P. Cordes, R. M. Hewick, M. J. Kriz, D. P. Lux- 
enberg, B. S. Sibley,  and J. M. Wozney. 1988.  Purification  and charac- 
terization of other distinct bone-inducing factors. Proc.  Natl.  Acod.  Sci. 
USA.  85:9484-9488. 
40. Wang, E. A., V. Rosen, J. S. D'Alessandro, M. Bauduy, P. Cordes, T. 
Harada, D. 1. Israel, R. M. Hewick, K. M. Kerns, P. LaPan, D. P. Lux- 
enberg, D. McQuaid, I. K. Moutsatsos, J.  Nove, and J. M. Wozney. 
1990. Recombinant  human  bone morphogenetic  protein induces bone for- 
mation. Proc.  Natl.  Acad.  Sci.  USA.  87:2220-2224. 
41. Wozney, J. M., V. Rosen, A. J. Celeste, L. M. Mitsock, M. I. Whitters, 
R. W. Kriz, R. M. Hewick, and E. A. Wang. 1988.  Novel regulators 
of bone formation: molecular clones and activity. Science (wash. DC). 
242:1528-1534. 
42. Wozney, J. M. 1989. Bone morphogenetic proteins. Prog. Growth Factor 
Res.  1:267-280. 
43. Yaffe, D. 1968. Retention of differentiation  potentialities during prolonged 
cultivation of myogenic cells. Proc. Natl. Acad. Sci.  USA. 61:477-483. 
44. Yarnaguchi, A., and A. J. Kahn. 1991. Osteogenic cell lines express myo- 
genic and adipocytic developmental potential.  Calcif ?~ssue Int. In press. 
45. Yoon, K., R. Buenaga, and G. A'. Rodan. 1987. Tissue specificity and de- 
velopmental expression of rat osteopontin. Biochem.  Biophys.  Res. Com- 
mun.  148:1129-1136. 
Yamaguchi et al. BMP-2 Modulates Osteoblastic  and Myogenic Differentiation  687 